Theranos Case: Clinical Evidence, Investor Fraud and Governance Lessons
Theranos sold a compelling vision, but healthcare claims must survive clinical validation, laboratory quality controls and regulator scrutiny.
Current position
Elizabeth Holmes was convicted in January 2022 on investor-fraud counts and sentenced in November 2022 to 135 months in federal prison. Ramesh “Sunny” Balwani was separately convicted and sentenced. The verdicts were not identical on every count, so articles should not state that every patient-related allegation resulted in a conviction against Holmes.
Key facts at a glance
| Holmes verdict | January 2022 |
|---|---|
| Holmes sentence | 135 months, imposed November 2022 |
| Balwani | Separately convicted and sentenced |
| Legal nuance | Counts and verdicts differed between defendants |
What this means in practice
A demo is not validation
A prototype can support product development, but clinical performance requires properly designed studies, comparator methods, quality systems and transparent limitations.
Expert boards must be able to challenge
Prestige does not replace relevant laboratory, diagnostics, regulatory and statistical expertise. Independent directors need access to underlying evidence.
Investor diligence must inspect the claim chain
For regulated products, ask what is approved, what is validated, what is performed on third-party equipment and what customers are actually told.
Practical example
A startup claims one sample can run 200 tests. Diligence should request test-by-test validation, failure rates, comparator data, regulator status and the proportion actually processed on the company’s own device.
A practical decision framework
1. Define the exact claim
Identify the entity, product, transaction, period and legal forum. Do not apply a headline about one company, order or market event to a different fact pattern.
2. Reconcile the economics
Trace the claim to cash flow, balance-sheet exposure, contractual rights and the measurement definition. Separate revenue from transaction value, profit from liquidity and allegation from final outcome.
3. Check the operative record
Read the latest primary document and note whether it is a policy paper, interim order, final order, judgment, agreement, filing or historical report.
4. Convert the lesson into a control
Assign an owner, deadline, evidence requirement and escalation threshold. A lesson is useful only when it changes a decision or control.
Action checklist
- Match each product claim to a validation report.
- Confirm regulator and laboratory status directly.
- Put domain experts on the board and audit committee.
- Protect technical whistleblowers and document responses.
- Separate research-stage capability from commercial claims.
Evidence and document checklist
- Clinical validation protocols and results
- Regulator and laboratory records
- Quality-control and proficiency-testing data
- Marketing claims and customer disclosures
- Board minutes and whistleblower investigations
Common mistakes and red flags
Common mistakes
- Treating patents as proof of clinical accuracy
- Using investor demonstrations as validation
- Building a board without domain expertise
- Threatening employees who raise scientific concerns
Red flags
- Claims exceed published validation scope
- Third-party machines are used but not disclosed
- Regulator findings are minimised internally
- Failure data is withheld from the board
Escalation route
For regulated products or proceedings, start with the responsible entity’s grievance or compliance channel and preserve written records. Use the relevant regulator, exchange, court or tribunal process where applicable. Obtain specialist advice before a limitation period, filing deadline, tax position or material right is affected.